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Available online 1 June 2016A serum Certiﬁed Reference Material (CRM) for supporting reliable autoimmune diagnostics was recently re-
leased by the Institute for ReferenceMaterials andMeasurements (IRMM) of the Joint Research Centre of the Eu-
ropean Commission. It was produced in collaboration with a Working Group on the Harmonisation of
Autoimmune Tests of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC WG-
HAT). This material is aimed at facilitating the standardisation of measurements of anti-myeloperoxidase immu-
noglobulin G antibodies. The CRM could be used as a common calibrant by clinicians andmanufacturers thereby
signiﬁcantly improving the comparability of results from commercial immunoassays used for IgG anti-MPOmea-
surements. This paper provides information on the new CRM and its intended use.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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There are currently more than 70 diseases resulting from the
body's immune system targeting its organs, tissues, cells and their
components [1] rather than destroying invader cells or infectious or-
ganisms (viruses or bacteria). Many of these autoimmune diseases
are characterised by the presence of speciﬁc autoantibodies. For ex-
ample, anti-myeloperoxidase (anti-MPO) and anti-proteinase 3
(anti-PR3) are present in ANCA-associated vasculitides [2–5]. Clini-
cians rely on the detection and quantiﬁcation of these autoanti-
bodies for the diagnosis and treatment of the diseases. The need for
quantitative information has led to the development of a variety of
ELISA-based immunoassays, new assay principles are being devel-
oped and automation has become more common. Tests do not only
need to be analytically speciﬁc and sensitive but should preferably
also show small inter-method variation in order to establish common
reference ranges, consistent “cut-off” values and clinical speciﬁcity
and sensitivity [6]. Some issues are contributing to the variability of re-
sults, including molecular heterogeneity of the antigen and antibody
target, performance variation between the different assays and also
lot-to-lot variation within assays. There is currently no robust
standardisation which contributes signiﬁcantly to the variation of re-
sults obtained by different laboratories [7]. For instance, the UKNationaltion of autoantibody tests (WG-
. This is an open access article underExternal Quality Assessment Service (UKNEQAS) has reported that the
measurement interval for “negative” samples for IgG anti-PR3 antibod-
ies can overlap with the values obtained for samples categorised as
“positive” (UKNEQAS for ANCA distributions 132 and 134). A similar
overlap in values for negative and positive samples has been shown in
the UKNEQAS scheme for IgG anti-MPO.
A feasibility study by the International Federation of Clinical Chemis-
try and Laboratory Medicine (IFCC)Working Groupmeasured IgG anti-
MPO in samples from 30 patients who were investigated for ANCA-as-
sociated vasculitis by 7 different methods. Nine of the samples were
consistently classiﬁed as positive across the different methods and
only onewas consistently classiﬁed as negative. The remaining 20 sam-
ples gave contradictory classiﬁcation depending on the type of assay
used [8]. This highlights two problems - the extreme variation in the re-
ported quantitative values but also in the classiﬁcation of the samples in
terms of positive and negative. It is likely that these two issueswill need
to be addressed separately. However, Hutu et al. have shown that the
use of a common, commutable referencematerial would improve com-
parability of measurement results [8].
The challenges in establishing standards for complex biological mol-
ecules are well recognised. Antibodies are prone to degradation; they
may showvariations in afﬁnity and avidity,may consist of different sub-
classes, and have high molecular diversity. The preparation of a serum
based standardwithmultiple processing steps, including eventually pu-
riﬁcation and freeze-drying,may degrade the proteinsmaking thembe-
have differently from fresh serum samples. There are some possible
sources of raw material for producing such reference materials, eachthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[9]. The most effective approach for developing reference materials is
likely to use a combination of processes that link together. For example,
pooled patient samples or plasmapheresis ﬂuid would give a sufﬁcient
total volume of raw material and afﬁnity-puriﬁed autoantibodies are
likely to be used as a calibrant for assigning a property value to the pre-
pared candidate reference material.
2. Standardisation efforts
The Institute for Reference Materials and Measurements (IRMM) of
the Joint Research Centre of the European Commission is participating
in a Working Group on Harmonisation of Autoantibody Tests (WG-
HAT) of IFCC [10]. The WG aims at evaluating the main causes of vari-
ability for clinically critical autoantibody measurements, identifying
the autoantibodies for which a common calibrator would reduce the
inter-assay variability and identifying and producing the materials
that could be used for assay calibration. The ﬁnal goal of this initiative
is to prepare commutable certiﬁed reference materials with well-de-
ﬁned properties that would allow standardisation of autoantibody test-
ing. If properly implemented the standardisation using certiﬁed
reference materials should lead to comparable, harmonised measure-
ment results.
3. First model system for developing procedures
The certiﬁed reference material (CRM) ERM-DA476/IFCC certiﬁed
for its concentration of anti-MPO immunoglobulin G in human serum
is the ﬁrst outcome of the Working Group [11]. IgG anti-MPO is one of
the two antibody speciﬁcities seen in ANCA-associated vasculitis,
which includemicroscopic polyangiitis (MPA), eosinophilic granuloma-
tosis with polyangiitis (EGPA, initially known as Churg-Strauss Syn-
drome) [12] and granulomatosis with polyangiitis (GPA, formerly
Wegener's Granulomatosis) [13]. These conditions mostly affect small
arteries, such as arterioles [14], and although they are rare diseases,
they can be very serious; symptoms can range in severity from minor
to life threatening [14]. Early diagnosis and appropriate treatment are
vital for the patient's survival but the disease course can be variable
and there is still a high proportion of patients (almost 50%) who relapse
[15].
ERM-DA476/IFCC is amaterial prepared from a plasmapheresis sam-
ple of a patient diagnosedwith vasculitis, provided by Statens Serum In-
stitute (DK). It was chosen because of its high titre of MPO ANCA
autoantibodies and its commutability [8]. The term commutability re-
fers to the characteristic of a material to behave in the same manner
as clinical samples with regard to several measurement procedures
[16]. The plasmapheresis material was transformed into serum (deﬁ-
brinated) through a process described elsewhere [17] and processed ac-
cording to a procedure similar to that used for other serum protein
reference materials [17]. The serum was delipidated and ﬁltered and
three preservatives were added (sodium azide, aprotinin andTable 1
Summary of advantages and disadvantages of the different types of starting material.
Pooled serum Afﬁnity pur
Advantages • Wide range of speciﬁcities within a particular antibody
• Polyclonal
• Possibly representative of most antibodies in most pa-
tients
• Small amounts from each patient needed
• Large total volumes can be collected
• Many pot
• Can blend
different i
• Long term
Disadvantages • Other proteins in serum may interfere
• Interactions between antibodies in different samples e.g.
rheumatoid factor
• Likely to be variable on long term
• Need rele
• Need larg
• May not b
all patien
• Need for sbenzamidine hydrochloridemonohydrate). Thematerial was then ﬁlter
sterilised through a 0.22 μmPES ﬁlter (Corning Incorporated, USA), fur-
ther diluted 1:6 with Zenalb® 4.5 (Bio Products Laboratory) and ﬁlled
into 1 mL colourless, siliconised glass vials before lyophilisation under
a low-pressure nitrogen atmosphere [11]. A concentration value for
the IgG speciﬁc against myeloperoxidase was assigned to the material
through an interlaboratory comparison involving ten laboratories.
These laboratories were requested to use their own, routine MPO
ANCA assays (ELISA, chemiluminescent and ﬂuoroenzyme immunoas-
says) to measure dilutions of the reference material ERM-DA476/IFCC
and dilutions of afﬁnity-puriﬁedMPOANCA. The solution of afﬁnity-pu-
riﬁed IgG had a value assigned using nephelometry and turbidimetry,
calibrated with the reference material ERM-DA470k/IFCC, which has a
certiﬁed value for total IgG [18]. The detailed process of the characteri-
sation is published in the certiﬁcation report of the CRM [11]. The mea-
surement results for ERM-DA476/IFCC show that the 9 different assays
perform well in terms of precision, but are using entirely different mea-
surement scales (Fig. 1, without common calibrant). Even when using
the same unit (IU/mL), the results varied from 40 to 356 IU/mL [11].
When the measured values for ERM-DA476/IFCC were recalibrated for
each assay according to the response for afﬁnity-puriﬁed IgG, the variation
was reduced to 13% (Fig. 1, with common calibrant). Consequently it was
possible to assign a certiﬁed value for MPO ANCA to ERM-DA476/IFCC,
traceable to the value for the IgG concentration in ERM-DA470k/IFCC.
4. Intended use
The main purpose of this certiﬁed reference material is the calibra-
tion of immunoassay-based in vitro diagnostic devices or calibrators
for MPO ANCA. It can also be used to maintain control charts and/or
for validation studies of methods for which the CRM has been shown
to be commutable. It is expected that the use of the CRM can put results
from different methods on the same scale and could also help in reduc-
ing batch-to-batch variability.
It should be kept in mind that the complex nature of autoantibodies
may still cause signiﬁcant variation of the results for individual clinical
samples between methods and over time. The characteristics of the
“same” antibody fromdifferent patientsmay vary in terms of the subclass,
afﬁnity, avidity, and even properties such as glycosylation. Each of these
factors will have a variable impact on the measured results from different
methods. The use of a common referencematerial may improve the over-
all correlation between methods, but results will not be comparable
among all patient samples, when different targets are measured.
Overall, the use of this CRM is likely to be a step towards a better un-
derstanding of the parameters that inﬂuence quantitative results for IgG
MPO-ANCA.
5. Next autoimmune targets
The development of ERM-DA476/IFCC required extensive feasibility
studies and the design of procedures for commutability assessment,iﬁed Monoclonal
ential interferences avoided
material from patients or even of
sotypes
consistency
• Most potential interferences avoided
• Long term consistency
vant antigen in large amounts
e volumes of raw material
e representative of all antibodies in
ts
ophisticated facilities
• May not be representative of all antibodies
in all patients
• Difﬁcult to generate in large amounts
• Need for sophisticated facilities
Fig. 1. Comparison of response values for each laboratory participating in the study before
and after correctionwith the CRM. Samples of the CRM and puriﬁedMPOANCA serving as
calibrant, were sent to nine laboratories and tested with different ELISA-like techniques.
The black diamonds represent the reported results from the laboratories using their
own calibrant, while the white ones represent the results after being corrected with the
use of the values for the puriﬁed MPO ANCA. The detailed procedure can be found
elsewhere [11]. The participating laboratories were: Aesku Diagnostics, Bio-Rad
Laboratories, Inc., Euro Diagnostica AB, Euroimmun AG, IMMCO Diagnostics, INOVA
Diagnostics, INC., Phadia GmbH.
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dures will now be used for the development of other CRMs for autoim-
mune targets.
Presently, the IRMM is in collaboration with the IFCC in the process
of preparing a CRM for anti-PR3 IgG autoantibodies. These autoanti-
bodies are found in approximately 80% of patients with GPA and
about 35% of patients with MPA and EGPA [19]. Additionally, the devel-
opment of a CRM for anti-B2 glycoprotein has progressed signiﬁcantly;
the characterisation of this material is ongoing.
Other approachesmay be needed for futurematerials. Therefore, the
IFCC-WG HAT is also investigating different approaches for obtaining
raw materials (e.g. pooled patient sera) and the possibility of using
monoclonal calibration material. In Table 1, the advantages and disad-
vantages of using different raw materials is summarised. Altogether,
the expertise developed should make it possible to produce CRMs for
autoimmune testing more efﬁciently and to improve measurement
comparability where possible.
6. Conclusions
New immunoassays, targeting different analytes and occasionally
employing different principles are being produced. At the same time,
the need for fast and reliable quantitative tests for the diagnosis of the
various autoimmune diseases is increasing. However, as shown in
some studies, there is still huge diversity in the results obtained by
these immunoassays. Therefore, high-quality CRMs to be used as
calibrants for in vitro diagnostics will help to foster comparability of
measurement results. At the moment, a ﬁrst material, for autoanti-
bodies against anti-MPO, has been produced and is available to labora-
tories and manufacturers [20].
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